Open in Screener

TRDA

Entrada Therapeutics Inc

May 21 • 04:00PM ET

6.31

+0.27 4.47 %

Healthcare • Biotechnology • USA • Micro • NASD

| Held by: VTI IWM VXF VTWO IWN IBB VHT SCHA DFAS IWC

Index	RUT	P/E	-	EPS (ttm)	-4.00	Insider Own	44.43%	Shs Outstand	38.82M	Perf Week	-7.61%
Market Cap	244.96M	Forward P/E	-	EPS next Y	-3.58	Insider Trans	-0.34%	Shs Float	21.57M	Perf Month	-51.65%
Enterprise Value	39.85M	PEG	-	EPS next Q	-1.06	Inst Own	48.14%	Short Float	4.63%	Perf Quarter	-44.11%
Income	-166.12M	P/S	42.68	EPS this Y	-14.20%	Inst Trans	-12.67%	Short Ratio	2.85	Perf Half Y	-28.46%
Sales	5.74M	P/B	0.90	EPS next Y	9.66%	ROA	-40.42%	Short Interest	1.00M	Perf YTD	-38.62%
Book/sh	6.98	P/C	0.96	EPS next 5Y	1.05%	ROE	-48.28%	52W High	16.45 -61.64%	Perf Year	-17.95%
Cash/sh	6.56	P/FCF	-	EPS past 3/5Y	-4.74% -32.56%	ROIC	-52.52%	52W Low	4.93 27.99%	Perf 3Y	-49.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	30.45%	Volatility	7.48% 9.88%	Perf 5Y	-
Dividend TTM	-	EV/Sales	6.94	EPS Y/Y TTM	-559.52%	Oper. Margin	-3076.18%	ATR (14)	1.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.90	Sales Y/Y TTM	-96.67%	Profit Margin	-2895.05%	RSI (14)	30.20	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	13.90	EPS Q/Q	-124.74%	SMA20	-36.58%	Beta	-0.19	Target Price	19.60
Payout	-	Debt/Eq	0.18	Sales Q/Q	-95.74%	SMA50	-46.25%	Rel Volume	1.06	Prev Close	6.04
Employees	152	LT Debt/Eq	0.17	Earnings	May 07 BMO	SMA200	-32.40%	Avg Volume	350.41K	Price	6.31
IPO	Oct 29, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.36% -70.03%	Trades		Volume	371,942	Change	4.47%

Date	Action	Analyst	Rating Change	Price Target Change
May-08-26	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-01-26	Initiated	Cantor Fitzgerald	Overweight
Feb-11-26	Initiated	Guggenheim	Buy	$20
Jan-28-26	Initiated	Oppenheimer	Outperform	$21
Dec-06-24	Initiated	ROTH MKM	Buy	$29
Jan-05-24	Initiated	Oppenheimer	Outperform	$22
Apr-03-23	Initiated	H.C. Wainwright	Buy	$25

May-08-26 06:39AM	Entradas stock drops as DMD drugs efficacy falls short (Clinical Trials Arena)
May-07-26 07:14AM	Entrada shares dive as Duchenne results disappoint (BioPharma Dive) -57.27%
07:10AM	Entrada Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire)
07:00AM	Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study (GlobeNewswire)
May-06-26 04:30PM	Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 (GlobeNewswire)
04:30PM	Loading…
Mar-02-26 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-26 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) +6.76%
Feb-25-26 07:25PM	Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-24-26 09:40AM	Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-19-26 10:00AM	Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline (Zacks)
Feb-18-26 07:58AM	EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? (Zacks)
Feb-17-26 07:00AM	Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study (GlobeNewswire)
Feb-15-26 03:02PM	Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit (MarketBeat)
Feb-05-26 06:00PM	Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates (Zacks) -6.93% +5.26%
Feb-04-26 07:40AM	Techne (TECH) Beats Q2 Earnings and Revenue Estimates (Zacks) -8.23%
07:00AM	Loading…
07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-09-26 07:16AM	Entrada Therapeutics reports progress across development portfolio (TipRanks)
Jan-08-26 07:00AM	Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases (GlobeNewswire)
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
Dec-17-25 07:00AM	Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 08:30AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-30-25 08:10AM	Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-29-25 07:46AM	Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last? (Zacks) -6.26%
Oct-28-25 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-05-25 07:00AM	Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program (GlobeNewswire)
Sep-02-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
10:15AM	Loading…
Jul-31-25 10:15AM	Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -11.45%
Jun-03-25 07:00AM	Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire)
Jun-02-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.11%
May-29-25 11:10AM	Entradas Phase I/II trial of DMD treatment authorised to begin in EU (Clinical Trials Arena)
May-28-25 07:00AM	Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
May-08-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.64%
07:00AM	Entrada Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
08:00AM	Arvinas, Entrada cut staff; Merck builds US hub for Keytruda (BioPharma Dive)
Apr-29-25 10:01AM	Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-10-25 09:30AM	Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? (Zacks) -5.08%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-25-25 10:03AM	Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment (Clinical Trials Arena) -5.79%
Mar-24-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
Feb-27-25 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 06:11AM	AstraZenecas next breast cancer drug; Madrigals accelerating MASH launch (BioPharma Dive)
Feb-25-25 01:05PM	FDA removes clinical hold on Entradas Duchenne therapy (Clinical Trials Arena) -5.68%
Feb-24-25 07:00AM	Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 (GlobeNewswire)
Feb-12-25 07:58AM	Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-04-25 07:19AM	Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment (Clinical Trials Arena)
Feb-03-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-30-25 04:05PM	Azenta Announces the Election of Dipal Doshi to its Board of Directors (PR Newswire)
Dec-18-24 07:00AM	Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.32%
Dec-07-24 05:25AM	Roth MKM starts overlooked Entrada Therapeutics with Buy rating (TipRanks)
Nov-25-24 08:50AM	Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-05-24 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-09-24 07:00AM	Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-24-24 07:00AM	Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development (GlobeNewswire) +5.70%
Sep-17-24 08:30AM	ashibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors (Business Wire)
Sep-06-24 07:00AM	Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program (GlobeNewswire)
Aug-13-24 08:20AM	Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates (Zacks) +11.26%
07:00AM	Entrada Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 09:55AM	Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High? (Zacks) +5.75%
Jul-12-24 09:33AM	Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last? (Zacks)
Jun-24-24 07:15AM	Entrada Therapeutics Announces $100 Million Registered Direct Offering (GlobeNewswire)
06:00AM	Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-03-24 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 09:55AM	Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet (Zacks)
May-20-24 05:32PM	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing (MT Newswires)
May-16-24 07:02PM	Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
04:35PM	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing (MT Newswires)
07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-07-24 01:53PM	TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Entrada Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-10-24 03:29PM	Insiders are Piling into These 5 Healthcare Stocks in 2024 (Insider Monkey) -5.72%
Apr-04-24 02:00PM	The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. (PR Newswire)
Mar-27-24 01:27AM	Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
Mar-15-24 05:31AM	Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials (GuruFocus.com)
Mar-13-24 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.76%
Feb-07-24 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-24 08:14AM	Time to Pull the Trigger, Says Oppenheimer About These 3 Stocks (TipRanks)
Jan-03-24 07:00AM	Entrada Therapeutics Promotes Nathan J. Dowden to President (GlobeNewswire) -9.03%
Dec-28-23 07:01AM	Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares (GuruFocus.com)
Nov-23-23 11:47AM	Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug (Zacks)
Nov-22-23 07:00AM	Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -31.85%
Nov-07-23 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +8.63%
08:06AM	Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million (GuruFocus.com)
07:00AM	Entrada Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-12-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -9.47%
Sep-21-23 07:00AM	Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-16-23 01:01AM	Insider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 Shares (GuruFocus.com)
Sep-07-23 07:00AM	Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community (GlobeNewswire) +5.48%
Aug-29-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Entrada Therapeutics Appoints Gina Chapman to its Board of Directors (GlobeNewswire)
Aug-08-23 08:40AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +10.47%
07:00AM	Entrada Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 06:36AM	Entrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 year (Simply Wall St.)
Aug-01-23 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company's oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

CEO & DirectorMr. Dipal Doshi

President & COOMr. Nathan J. Dowden

President of Research & DevelopmentDr. Natarajan Sethuraman Ph.D.

CFO & TreasurerMr. Kory James Wentworth CPA

Ph.D.Dr. Jared Cohen J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zeiher Bernhardt G	Director	May 20 '26	Buy	5.86	5,000	29,316	5,000	May 21 04:31 PM
Sethuraman Natarajan	President, Research & Develop.	May 04 '26	Sale	15.39	25,907	398,810	216,317	May 04 07:25 PM
Dowden Nathan J	President & COO	May 04 '26	Option Exercise	1.74	15,000	26,100	213,588	May 04 07:24 PM
Dowden Nathan J	President & COO	May 04 '26	Sale	15.33	15,000	229,953	198,588	May 04 07:24 PM
NATHAN DOWDEN	Officer	May 04 '26	Proposed Sale	14.50	15,000	217,500		May 04 04:33 PM
NATARAJAN SETHURAMAN	Officer	May 04 '26	Proposed Sale	14.50	25,907	375,652		May 04 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Apr 01 '26	Sale	12.95	2,500	32,375	119,010	Apr 02 04:39 PM
KORY WENTWORTH	Officer	Apr 01 '26	Proposed Sale	12.62	2,500	31,550		Apr 01 04:38 PM
Dowden Nathan J	President & COO	Mar 10 '26	Sale	13.05	11,894	155,188	198,588	Mar 11 04:35 PM
Dowden Nathan J	President & COO	Mar 09 '26	Sale	13.02	3,116	40,583	210,482	Mar 11 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 10 '26	Sale	13.02	11,388	148,216	121,510	Mar 11 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 09 '26	Sale	13.00	5,089	66,163	132,898	Mar 11 04:34 PM
KORY WENTWORTH	Officer	Mar 09 '26	Proposed Sale	12.58	16,477	207,281		Mar 09 04:37 PM
NATHAN DOWDEN	Officer	Mar 09 '26	Proposed Sale	12.58	15,010	188,826		Mar 09 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 04 '26	Sale	12.25	7,988	97,892	137,987	Mar 06 04:36 PM
KORY WENTWORTH	Officer	Mar 04 '26	Proposed Sale	11.85	7,988	94,658		Mar 04 05:11 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 21 '25	Sale	9.98	8,910	88,932	110,026	Nov 24 04:30 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 20 '25	Buy	9.07	28,867	261,846	4,691,392	Nov 24 04:09 PM
KORY WENTWORTH	Officer	Nov 21 '25	Proposed Sale	9.17	8,910	81,705		Nov 21 04:45 PM
PARMAR KUSH	Director	Nov 14 '25	Sale	8.80	200,000	1,760,000	2,963,066	Nov 18 04:36 PM
5AM Ventures V, L.P.	10% Owner	Nov 14 '25	Sale	8.80	200,000	1,760,000	2,963,066	Nov 18 04:34 PM
5AM Ventures V, L.P.	Affiliated Stockholder	Nov 14 '25	Proposed Sale	8.80	200,000	1,760,664		Nov 14 04:30 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 12 '25	Buy	7.76	100,736	781,638	4,664,924	Nov 12 05:34 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 11 '25	Buy	7.50	46,434	348,193	4,572,549	Nov 12 05:34 PM
BAKER BROS. ADVISORS LP	10% Owner	Nov 10 '25	Buy	7.21	30,874	222,756	4,529,969	Nov 12 05:34 PM
PARMAR KUSH	Director	Jul 09 '25	Sale	7.50	27,000	202,554	1,093,313	Jul 11 05:27 PM
5AM Ventures V, L.P.	10% Owner	Jul 09 '25	Sale	7.50	20,065	150,528	3,163,066	Jul 11 05:25 PM
5AM Ventures V, L.P.	10% Owner	Jul 09 '25	Sale	7.50	6,935	52,026	1,093,313	Jul 11 05:25 PM
5AM Opportunities I, L.P.	Director	Jul 09 '25	Proposed Sale	7.50	6,935	52,025		Jul 09 05:04 PM
5AM Ventures V, L.P.	Director	Jul 09 '25	Proposed Sale	7.50	20,065	150,528		Jul 09 05:02 PM
PARMAR KUSH	Director	Jun 27 '25	Sale	6.91	75,000	518,250	1,113,092	Jul 01 08:33 PM
PARMAR KUSH	Director	Jul 01 '25	Sale	7.12	25,000	178,065	1,100,248	Jul 01 08:33 PM
PARMAR KUSH	Director	Jun 30 '25	Sale	6.81	25,000	170,318	1,106,670	Jul 01 08:33 PM
5AM Ventures V, L.P.	10% Owner	Jun 27 '25	Sale	6.91	55,735	385,129	3,220,287	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jun 27 '25	Sale	6.91	19,265	133,121	1,113,092	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jul 01 '25	Sale	7.12	18,578	132,324	3,183,131	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jun 30 '25	Sale	6.81	18,578	126,566	3,201,709	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jul 01 '25	Sale	7.12	6,422	45,741	1,100,248	Jul 01 08:32 PM
5AM Ventures V, L.P.	10% Owner	Jun 30 '25	Sale	6.81	6,422	43,751	1,106,670	Jul 01 08:32 PM
5AM Ventures V, L.P.	Director	Jul 01 '25	Proposed Sale	7.12	18,578	132,324		Jul 01 05:03 PM
5AM Opportunities I, L.P.	Director	Jul 01 '25	Proposed Sale	7.12	6,422	45,737		Jul 01 05:01 PM
5AM Opportunities I, L.P.	Director	Jun 30 '25	Proposed Sale	6.81	6,422	43,751		Jun 30 05:09 PM
5AM Ventures V, L.P.	Director	Jun 30 '25	Proposed Sale	6.81	18,578	126,566		Jun 30 05:06 PM
5AM Opportunities I, L.P.	Director	Jun 27 '25	Proposed Sale	6.91	19,265	133,121		Jun 27 05:05 PM
5AM Ventures V, L.P.	Director	Jun 27 '25	Proposed Sale	6.91	55,735	385,129		Jun 27 05:03 PM

AMLX Amylyx Pharmaceuticals Inc daily Stock Chart

Peers: PTCT ACAD SUPN FOLD RYTM

| Held by: VTI IWM VXF IBB IWO VTWO XPH SCHA IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-1.51	Insider Own	16.83%	Shs Outstand	111.03M	Perf Week	0.36%
Market Cap	1.55B	Forward P/E	-	EPS next Y	-1.27	Insider Trans	-2.07%	Shs Float	92.48M	Perf Month	-20.49%
Enterprise Value	1.27B	PEG	-	EPS next Q	-0.35	Inst Own	96.18%	Short Float	16.00%	Perf Quarter	-0.57%
Income	-150.11M	P/S	-	EPS this Y	7.86%	Inst Trans	0.65%	Short Ratio	13.21	Perf Half Y	-0.14%
Sales	0.00M	P/B	5.66	EPS next Y	9.85%	ROA	-58.49%	Short Interest	14.80M	Perf YTD	15.31%
Book/sh	2.46	P/C	5.54	EPS next 5Y	27.97%	ROE	-63.26%	52W High	18.60 -25.13%	Perf Year	156.54%
Cash/sh	2.52	P/FCF	-	EPS past 3/5Y	19.94% -15.37%	ROIC	-54.07%	52W Low	4.64 200.22%	Perf 3Y	-47.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.05% 5.57%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	51.42%	Oper. Margin	-	ATR (14)	0.82	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.85	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	41.17	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	17.85	EPS Q/Q	10.88%	SMA20	-7.42%	Beta	-0.14	Target Price	23.40
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-8.70%	Rel Volume	0.91	Prev Close	13.61
Employees	136	LT Debt/Eq	0.02	Earnings	May 07 BMO	SMA200	2.97%	Avg Volume	1.12M	Price	13.93
IPO	Jan 07, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.50% -	Trades		Volume	1,021,636	Change	2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-03-26	Initiated	Stifel	Buy	$21
Jul-10-25	Resumed	Goldman	Buy	$10
Jun-24-25	Initiated	Guggenheim	Buy	$17
Jun-17-25	Initiated	Citigroup	Buy	$12
May-30-25	Initiated	TD Cowen	Buy
Apr-07-25	Upgrade	Mizuho	Neutral → Outperform	$7
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform	$3 → $11
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy	$4.20 → $10
Mar-18-24	Downgrade	Mizuho	Buy → Neutral	$32 → $4
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral	$37 → $4
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27 → $4
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jan-03-24	Initiated	Robert W. Baird	Outperform	$37
Dec-12-23	Initiated	Deutsche Bank	Buy	$36
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Show Previous Ratings

May-07-26 07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results (Business Wire) -5.35%
May-05-26 07:00AM	Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia (Business Wire)
Apr-30-26 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Apr-09-26 07:54PM	Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire) -5.54%
Apr-08-26 09:00AM	Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
07:00AM	Loading…
Mar-24-26 07:00AM	Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia (Business Wire)
Mar-04-26 08:02PM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) +6.66% -6.31%
03:57AM	Amylyx Pharmaceuticals Says 2026 Could Be Transformative Ahead of Avexitide Phase 3 Readout (MarketBeat)
Mar-03-26 12:32PM	Amylyx Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby) -7.78%
11:18AM	Amylyx Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
07:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-26-26 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences (Business Wire) +6.19%
Feb-24-26 09:00AM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 (Business Wire) +5.83%
Jan-29-26 05:05PM	HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Jan-19-26 08:01AM	Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders (Insider Monkey)
02:57PM	Loading…
Jan-10-26 02:57PM	Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases (Insider Monkey)
Jan-09-26 07:16AM	Amylyx selects AMX0318 as development candidate for PBH (TipRanks)
Jan-08-26 07:00AM	Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S (Business Wire)
Dec-12-25 04:35AM	Amylyx pins its next hopes on a niche drug in the obesity space (Pharma Voice)
Dec-05-25 09:00AM	Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial (Business Wire)
Nov-28-25 06:40PM	HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Nov-10-25 09:40AM	Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-06-25 02:12PM	Amylyx Pharmaceuticals Inc (AMLX) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com) -5.89%
07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 09:00AM	Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Oct-30-25 09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Oct-27-25 12:20PM	Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-26-25 06:16AM	BofA Securities Lifts Amylyx Pharmaceuticals Inc. (AMLX) Price Target Amid Bolstered Balance Sheet (Insider Monkey)
Oct-24-25 12:00PM	What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now? (Zacks)
09:55AM	Wall Street Analysts See a 29.28% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? (Zacks)
09:40AM	Loading…
09:40AM	Has Amylyx Pharmaceuticals (AMLX) Outpaced Other Medical Stocks This Year? (Zacks)
Oct-16-25 04:43PM	Is AMLX Stock a Solid Choice Right Now? (Zacks)
Sep-10-25 12:06AM	Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock (Business Wire) +12.56%
Sep-09-25 04:01PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Aug-27-25 12:35PM	Amylyx culls rare neurological disorder programme after trial failure (Pharmaceutical Technology)
12:24PM	Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial (Benzinga)
07:22AM	Amylyx drug comes up short; Sanofi names new CMO (BioPharma Dive)
07:00AM	Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) (Business Wire)
Aug-19-25 12:07AM	H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm 'Buy' Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) (Insider Monkey)
Aug-07-25 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-31-25 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-15-25 08:58AM	Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion (Insider Monkey)
Jul-14-25 11:52AM	Amylyx presents new exploratory analyses from avexitide trials for PBH (Clinical Trials Arena) +9.51%
Jul-13-25 05:00PM	Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 (Business Wire)
Jul-08-25 07:00AM	Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025 (Business Wire)
Jun-27-25 07:56AM	Why Shares in Amylyx Pharmaceuticals Soared This Week (Motley Fool)
Jun-25-25 03:27AM	After myriad failures, a new wave of ALS drugs approaches (Pharma Voice)
Jun-24-25 12:46PM	Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114 (Insider Monkey) +27.69%
Jun-03-25 07:00AM	Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
May-21-25 07:00AM	Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences (Business Wire)
May-20-25 09:55AM	Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? (Zacks)
May-12-25 07:00AM	Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome (Business Wire)
May-09-25 03:12AM	Amylyx Pharmaceuticals Inc (AMLX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-08-25 07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results (Business Wire) -5.95%
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
08:00AM	Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences (Business Wire)
May-01-25 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
06:06AM	Amylyx doses first subject in trial of post-bariatric hypoglycaemia treatment (Clinical Trials Arena)
Apr-30-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia (Business Wire)
Apr-16-25 11:22AM	Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-11-25 08:11AM	Amgen says Imdelltra extended survival; Parker Institute adds new leaders (BioPharma Dive)
Apr-10-25 07:03AM	First subject dosed in Amylyxs Phase I trial of ALS therapy (Clinical Trials Arena)
Apr-09-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis (Business Wire) +5.44%
Apr-02-25 09:00AM	Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) +13.17%
Mar-27-25 10:17AM	Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-05-25 10:01AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +11.63%
Mar-04-25 06:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Mar-03-25 07:18AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -8.54%
Feb-25-25 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-24-25 09:00AM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 (Business Wire) -9.09%
Feb-10-25 09:00AM	Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-31-25 12:00PM	Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive)
Jan-21-25 09:00AM	Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
Jan-10-25 08:26AM	Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire) -7.16%
Jan-09-25 07:30PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-06-25 09:00AM	Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer (Business Wire) -5.54%
Dec-30-24 02:52PM	Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-05-24 07:35AM	Amylyx announces design of LUCIDITY clinical trial (TipRanks) -5.51%
Dec-04-24 07:30AM	Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia (Business Wire)
Nov-27-24 09:00AM	Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire) +5.32%
Nov-08-24 02:11AM	Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:33AM	Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results (Business Wire) +5.14%
Nov-04-24 09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-25-24 09:05PM	Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc (GuruFocus.com) +8.37%
Oct-19-24 11:12AM	Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments (Insider Monkey)
Oct-18-24 07:34AM	Amylyxs AMX0035 shows promise in Phase II Wolfram syndrome trial (Clinical Trials Arena) +21.94%
07:26AM	Why Amylyx Pharmaceuticals Stock Was So Healthy This Week (Motley Fool)
07:04AM	PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug (BioPharma Dive)
Oct-17-24 09:00AM	Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome (Business Wire)
Oct-15-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 (Business Wire) +10.06%
Oct-09-24 05:32PM	Amylyx Pharmaceuticals Inc (AMLX) Q2 2024 Earnings Call Highlights: Strategic Pipeline ... (GuruFocus.com)
Sep-09-24 07:17PM	Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +6.33% +5.56%
Sep-06-24 01:49AM	Director MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +7.73%
Aug-28-24 08:30AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-24 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration (Business Wire)
Aug-08-24 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
04:32AM	EC grants orphan drug status for Amylyxs Wolfram treatment (Pharmaceutical Technology)

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx's pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Co-FounderMr. Joshua B. Cohen

Co-CEO & DirectorMr. Justin B. Klee

Chief Financial OfficerMr. James M. Frates M.B.A.

Chief Medical OfficerDr. Camille L. Bedrosian M.D.

Chief Technical Operations OfficerMr. Tom Holmes

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klee Justin B.	Co-Chief Executive Officer	Mar 02 '26	Sale	14.47	29,282	423,760	3,334,616	Mar 04 04:00 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 02 '26	Sale	14.48	29,282	424,120	3,334,683	Mar 04 04:00 PM
Bedrosian Camille L	Chief Medical Officer	Mar 02 '26	Sale	14.58	6,461	94,205	169,295	Mar 04 04:00 PM
FRATES JAMES M	Chief Financial Officer	Mar 02 '26	Sale	14.52	7,909	114,851	165,638	Mar 04 04:00 PM
Mazzariello Gina	Chief Legal Officer	Mar 02 '26	Sale	14.52	6,844	99,378	134,430	Mar 04 04:00 PM
Klee Justin B.	Officer	Mar 02 '26	Proposed Sale	14.47	29,282	423,760		Mar 02 04:30 PM
Frates James M	Officer	Mar 02 '26	Proposed Sale	14.52	7,909	114,852		Mar 02 04:30 PM
Bedrosian Camille L	Officer	Mar 02 '26	Proposed Sale	14.58	6,461	94,205		Mar 02 04:30 PM
Cohen Joshua B	Officer	Mar 02 '26	Proposed Sale	14.48	29,282	424,120		Mar 02 04:30 PM
Mazzariello Gina	Officer	Mar 02 '26	Proposed Sale	14.52	6,844	99,379		Mar 02 04:30 PM
Mazzariello Gina	Chief Legal Officer	Feb 23 '26	Sale	14.14	3,419	48,352	141,274	Feb 25 04:00 PM
Mazzariello Gina	Officer	Feb 23 '26	Proposed Sale	14.14	3,419	48,352		Feb 23 04:25 PM
FRATES JAMES M	Chief Financial Officer	Feb 02 '26	Sale	14.65	3,557	52,097	173,547	Feb 04 04:05 PM
Cohen Joshua B	Co-Chief Executive Officer	Feb 02 '26	Sale	14.68	15,500	227,593	3,363,965	Feb 04 04:05 PM
Mazzariello Gina	Chief Legal Officer	Feb 02 '26	Sale	14.65	3,448	50,516	144,693	Feb 04 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Feb 02 '26	Sale	14.69	15,500	227,618	3,363,898	Feb 04 04:05 PM
Klee Justin B.	Officer	Feb 02 '26	Proposed Sale	14.68	15,500	227,617		Feb 02 04:10 PM
Cohen Joshua B	Officer	Feb 02 '26	Proposed Sale	14.68	15,500	227,593		Feb 02 04:10 PM
Mazzariello Gina	Officer	Feb 02 '26	Proposed Sale	14.65	3,448	50,515		Feb 02 04:10 PM
Frates James M	Officer	Feb 02 '26	Proposed Sale	14.65	3,557	52,097		Feb 02 04:10 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 15 '26	Option Exercise	7.57	197,182	1,492,668	3,514,814	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 16 '26	Option Exercise	7.57	2,818	21,332	3,381,439	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 15 '26	Sale	13.59	136,193	1,850,795	3,378,621	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 16 '26	Sale	13.83	1,974	27,299	3,379,465	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 15 '26	Option Exercise	7.57	197,153	1,492,448	3,514,739	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 16 '26	Option Exercise	7.57	2,847	21,552	3,381,393	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 15 '26	Sale	13.58	136,193	1,849,869	3,378,546	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 16 '26	Sale	13.89	1,995	27,701	3,379,398	Jan 20 09:46 PM
JUSTIN KLEE	Director	Jan 16 '26	Proposed Sale	13.52	1,995	26,972		Jan 16 04:05 PM
JOSHUA COHEN	Director	Jan 16 '26	Proposed Sale	13.52	1,974	26,688		Jan 16 04:03 PM
JOSHUA COHEN	Director	Jan 15 '26	Proposed Sale	14.07	136,193	1,916,236		Jan 15 04:17 PM
JUSTIN KLEE	Director	Jan 15 '26	Proposed Sale	14.07	136,193	1,916,236		Jan 15 04:14 PM
FRATES JAMES M	Chief Financial Officer	Jan 06 '26	Sale	11.11	3,326	36,954	177,104	Jan 08 04:05 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 06 '26	Sale	11.09	7,715	85,596	3,317,632	Jan 08 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 06 '26	Sale	11.09	7,715	85,589	3,317,586	Jan 08 04:05 PM
Frates James M	Officer	Jan 06 '26	Proposed Sale	11.11	3,326	36,954		Jan 06 04:05 PM
Klee Justin B.	Officer	Jan 06 '26	Proposed Sale	11.09	7,715	85,590		Jan 06 04:05 PM
Cohen Joshua B	Officer	Jan 06 '26	Proposed Sale	11.09	7,715	85,597		Jan 06 04:04 PM
Firestone Karen	Director	Dec 23 '25	Buy	12.45	8,100	100,845	63,100	Dec 23 08:48 PM
Bedrosian Camille L	Chief Medical Officer	Dec 01 '25	Sale	14.35	6,580	94,418	175,756	Dec 03 04:39 PM
Bedrosian Camille L	Officer	Dec 01 '25	Proposed Sale	14.35	6,580	94,419		Dec 01 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Sep 30 '25	Sale	14.38	29,975	430,952	3,325,301	Oct 02 04:15 PM
Mazzariello Gina	Chief Legal Officer	Sep 30 '25	Sale	14.58	8,828	128,669	148,141	Oct 02 04:15 PM
FRATES JAMES M	Chief Financial Officer	Sep 30 '25	Sale	14.65	10,558	154,650	280,430	Oct 02 04:15 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 30 '25	Sale	14.35	29,933	429,469	3,325,347	Oct 02 04:15 PM
Bedrosian Camille L	Chief Medical Officer	Sep 30 '25	Sale	14.58	12,039	175,518	182,336	Oct 02 04:15 PM
Mazzariello Gina	Chief Legal Officer	Aug 13 '25	Sale	8.34	15,000	125,046	156,969	Aug 14 04:20 PM
Mazzariello Gina	Chief Legal Officer	Aug 12 '25	Sale	8.07	15,000	121,102	171,969	Aug 14 04:20 PM
GINA MAZZARIELLO	Officer	Aug 12 '25	Proposed Sale	7.82	30,000	234,600		Aug 12 04:25 PM

TRDA

Entrada Therapeutics Inc

AMLX

Amylyx Pharmaceuticals Inc

Upgrade your Finviz experience